ATF4 and Alzheimer disease: Two individuals (both females with moderate AD pathology, aged >89 years; table S3) were chosen for ChIP-seq analysis based on high prefrontal cortex CREB3L2 and ATF4 expression in addition to reduced postmortem processing intervals.